Inmazeb

Inmazeb is a combination of three different monoclonal antibodies used to treat infection from Zaire ebolavirus, commonly known as Ebola. Antibodies are proteins your body makes when it sees foreign substances called antigens. They attach to these antigens that are found on viruses, bacteria, and other substances your body doesn't recognize in your blood to help your body get rid of them. Inmazeb targets the Ebola virus in your body and destroys it so it doesn't make you sick. It also prevents the virus from entering into your cells and working normally.

Inmazeb is used to treat Ebola, which can be a deadly infection if not properly cared for. Signs and symptoms include fever, aches and pains, weakness and fatigue, and stomach problems. Ebola is spread through direct contact with an object or bodily fluid contaminated with Ebola virus. If you think you've been exposed to Ebola, seek medical attention right away so you can be tested and treated appropriately.

If you're located in the U.S., Inmazeb might not be readily available. There are selected healthcare facilities in the U.S. that are called designated Ebola treatment centers and might carry this treatment. The manufacturer (Regeneron) is currently supplying the Biomedical Advanced Research and Development Authority (BARDA) with a limited number of Inmazeb until 2026. This is part of the U.S. Department of Health and Human Services' (HHS) goal to be prepared for future public health emergencies. One of Regeneron's other priorities is working to make sure people in low- and middle-income countries where Ebola is more common, like the Democratic Republic of the Congo (DRC), can get this treatment.

Inmazeb is given as an injection through the veins (IV) by a healthcare provider. The IV infusion takes about 2 to 4 hours, depending on your weight.